Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients with hepatic/renal impairment-Reference-Cited by-同舟云学术

Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients with hepatic/renal impairment

Published:2022-08 Issue: Volume:133 Page:105210
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Wang Zhongjian,Liu Wei,Li Xueyan,Chen Hongjiao,Qi Dongying,Pan Fulu,Liu Huining,Yu Shuang,Yi Bowen,Wang Guopeng,Liu Yang^ORCID

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference48 articles.

1. Baricitinib: a review in rheumatoid arthritis;Al-Salama;Drugs,2018

2. Nano-encapsulation and characterization of baricitinib using poly-lactic-glycolic acid co-polymer;Ansari;Saudi Pharmaceut. J.,2019

3. Physiologically based pharmacokinetic models of probenecid and furosemide to predict transporter mediated drug-drug interactions;Britz;Pharm. Res. (N. Y.),2020

4. Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts;Dagli-Hernandez;Pharmacol. Rep.,2021

5. de Witte WEA, Danhof M, van der Graaf PH, de Lange ECM. In Vivo Target Residence Time and Kinetic Selectivity: the Association Rate Constant as Determinant. (1873-3735 (Electronic)).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach;BMC Pharmacology and Toxicology;2024-01-02

2. Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach;Cancer Chemotherapy and Pharmacology;2023-10-14

3. Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach;2023-06-09

4. Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption;ACS Omega;2022-12-15